Amit Singh, PhD
He received his Ph.D. in Biotechnology under the tutelage of Dr. Murali Sastry at National Chemical Laboratory, Pune, India (June, 2007). Amit joined Prof. Stephane Evoy at National Institute for Nanotechnology and University of Alberta, Canada as postdoctoral fellow working on Bacteriophage-based technology for pathogen detection. His current research interests include nanotechnology, material synthesis and characterization, nano-biotechnology, devices and sensors/biosensors, cancer cell imaging, diagnostics, drug delivery, and therapeutics. Linkedin, More..
Srinivas Reddy Boreddy, PhD
He received his Ph.D in Life Sciences from Indian Institute of Chemical Technology (IICT) under Osmania University, Hyderabad, India in 2008. Earlier, he worked as a Postdoctoral Research Associate at Texas Tech University Health Sciences Center, Amarillo, Texas on “evaluation of phytochemicals as potential drug candidates”. Presently, his research work focuses on SiRNA delivery and evaluating its therapeutic efficacy in genetically engineered mouse models (GEMM). His main research interests include novel drug target identification, drug development and developing oncology animal models. Linkedin
Srinivas Ganta, PhD
He is currently working as a Principal Scientist at Nemucore Medical Innovations, Inc., in Worcester, MA. He received his PhD in Pharmaceutical Sciences from the University of Auckland, New Zealand in 2008 and then worked as Associate Research Scientist in Prof. Amiji’s group in the Department of Pharmaceutical Sciences at Northeastern University. He has research interests in the area of novel drug delivery technologies for cancer treatment, and preclinical PK/PD assessment of nanomedicine. Linkedin
Ming Chen, PhD
He got his Ph.D from University of Massachusetts at Dartmouth in 2009. Before joining Dr. Amiji’s group, he was a Research Fellow in Dr. Martin Yarmush’s group at the Center for Engineering Medicine in Harvard Medical School/Massachusetts General Hospital/Shriners Childrens Hospital in Boston. Currently, his project focuses on the application of mitochondria-targeted ceramide delivered in tumor-targeted bidegradable engineered polymeric nanoparticles to overcome tumor multi drug resistance (MDR).